In 2019,Journal of Medicinal Chemistry included an article by Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke. Application of 89466-08-0. The article was titled 《Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)》. The information in the text is summarized as follows:
Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepared as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer. I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM. Cocrystallog. structure determination and computational investigation were conducted to elucidate its target selectivity. In the experimental materials used by the author, we found 2-Hydroxyphenylboronic acid(cas: 89466-08-0Application of 89466-08-0)
2-Hydroxyphenylboronic acid(cas: 89466-08-0) belongs to acyl phenylboronic acid. Phenylboronic acid (PBA) has been used to extract β-blockers (a class of aminoalcohol-containing drugs) from aqueous solution, rat, and human plasma. Application of 89466-08-0
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts